Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk

Journal of Orthopaedic Research

Volumn 27, Issue 10, 2009, Pages 1288-1292

  Burr, David B ^a,b   Diab, Tamim ^a   Koivunemi, Andrew ^a   Koivunemi, Mark ^a   Allen, Matthew R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

Author keywords

Biomechanics; Bisphosphonates; Femur; Subtrochanteric fractures

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE STRENGTH; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DOG; DRUG EFFECT; FEMUR FRACTURE; FEMUR SHAFT; FEMUR SUBTROCHANTERIC FRACTURE; MECHANICAL STRESS; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE DENSITY CONSERVATION AGENTS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL FRACTURES; FEMUR; OSTEOPOROSIS; RISK FACTORS;

EID: 70349218082     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20895     Document Type: Article

References (34)

1. Mashiba T, Hirano T, Turner CH, et al. 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620. (Pubitemid 30174014)
2. Mashiba T, Turner CH, Hirano T, et al. 2001. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531. (Pubitemid 32416465)
3. Allen MR, Iwata K, Phipps R, et al., 2006. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872-879. (Pubitemid 44311727)
4. Allen MR, Burr DB. 2007. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759-1765.
5. Allen MR, Reinwald S, Burr DB. 2008. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following three years of daily treatment. Calcif Tiss Int 82:354-360.
6. Allen MR, Burr DB. 2007. Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. BoneKEy-Osteovision 4:49-60.
7. Allen MR, Burr DB. 2008 Changes in vertebral strength - density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int 19:95-99.
8. Roschger P, Fratzl P, Klaushofer K, et al. 1997. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Bone 20:393-397. (Pubitemid 27230442)
9. Roschger P, Rinnerthaler S, Yates J, et al. 2001. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191. (Pubitemid 32737191)
10. Boivin G, Chavassieux PM, Santora AC, et al. 2000. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694. (Pubitemid 30808808)
11. Boivin G, Meunier PJ. 2002. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact 2:538-543.
12. Burr DB, Miller L, Grynpas M, et al. 2003. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33:960-969. (Pubitemid 37543573)
13. Wang X, Shen X, Li X, et al. 2002. Age-related changes in the collagen network and toughness of bone. Bone 31:1-7. (Pubitemid 34754417)
14. Vashishth D, Gibson GJ, Khoury JI, et al. 2001. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28:195-201. (Pubitemid 32140975)
15. Saito M, Fujii K, Marumo K. 2006. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 79:160-168. (Pubitemid 44440444)
16. Saito M, Fujii K, Soshi S, et al. 2006. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986-995. (Pubitemid 43864852)
17. Allen MR, Gineyts E, Leeming DJ, et al. 2008. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 19:329-337.
18. Siegmund T, Allen MR, Burr DB. 2008. Failure of mineralized collagen fibrils: Modeling the role of collagen cross-linking. J Biomech 41:1427-1435.
19. Cheung RKH, Leung KK, Lee KC, et al. 2007. Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 13:485-489.
20. Goh S-K, Yang KY, Koh JSB, et al. 2007. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg 89-B:349-353. (Pubitemid 46563912)
21. Demiralp B, Ilgan S, Ozgur Karacalioglu A, et al. 2007. Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: A case report. Arch Orthop Traum Surg 127:597-601. (Pubitemid 47226177)
22. Kwek EBK, Goh SK, Koh JSB, et al. 2008. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury Int J Care Injured 39:224-231.
23. Lenart BA, Lorich DG, Lane JM. 2008. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1305.
24. Neviaser AS, Lane JM, Lenart BA, et al. 2008. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346-350.
25. Visekruna M, Wilson D, McKiernan FE. 2008. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrin Metab 93:2948-2952.
26. Turner CH, Burr DB. 1993. Basic biomechanical measurements of bone. Bone 14:595-608.
27. Komatsubara S, Mori S, Mashiba T, et al. 2003. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512-520. (Pubitemid 36241068)
28. Allen MR, Hogan HA, Hobbs WA, et al. 2007. Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology 148:3908-3913.
29. Parfitt AM. 1983. The physiologic and clinical significance of bone histomorphometric data. In: Recker RR, editor. Bone histomorphometry: Techniques and interpretation. Boca Raton, FL: CRC Press, p 143-224.
30. Forwood MR, Burr DB, Takano Y, et al. 1995. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 16:643-650.
31. Diab T, Allen MR, Burr DB. 2009. Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. Osteoporos 20:647-652.
32. Tang SY, Allen MR, Phipps R, et al. 2008. Changes in nonenzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int doi 10.1007/s00198-008-0754-764
33. Komatsubara S, Mori S, Mashiba T, et al. 2004. Suppressed bone turnover by long-termbisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999-1005. (Pubitemid 41103457)
34. Allen MR, Follet H, Khurana M, et al. 2006. Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tiss Int 79:255-261. (Pubitemid 44673719)